Previous 10 | Next 10 |
FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and the depa...
FT MYERS, FL / ACCESSWIRE / May 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating in investor meetings and a fireside chat at the...
NeoGenomics, Inc. (NEO) Q1 2022 Earnings Conference Call April 27, 2022, 08:30 AM ET Company Participants Lynn Tetrault - Executive Chair & Principal Executive Officer William Bonello - Chief Financial Officer Doug Brown - Chief Strategy and Corporate Development Officer Charlie Eidson - ...
The following slide deck was published by NeoGenomics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: NeoGenomics, Inc. 2022 Q1 - Results - Earnings Call Presentation
NeoGenomics press release (NASDAQ:NEO): Q1 Non-GAAP EPS of -$0.20 beats by $0.04. Revenue of $117.17M (+1.4% Y/Y) beats by $0.73M. "While our first quarter performance was disappointing and inconsistent with our company's strong track record, we are taking immediate actions to improve our ope...
First-Quarter 2022 Results Consolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3% Clinical Services revenue increased 2% to $99 million; excluding 2021 COVID-19 PCR testing revenue, Clinical Services reve...
Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. Domestic mid-cap equities were volatile and notched a 12.6% quarterly decline in response to the event-filled start to 2...
NeoGenomics (NASDAQ:NEO) is scheduled to announce Q1 earnings results on Wednesday, April 27th, before market open. The consensus EPS Estimate is -$0.24 and the consensus Revenue Estimate is $116.44M (+0.8% Y/Y). Over the last 2 years, NEO has beaten EPS estimates 75% of the time and has...
FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that they are partnering with Eli Lilly and Company on a sponsored testing program for e...
Data demonstrates potential of RaDaR to predict clinical response in stage III urothelial cancer FT. MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, to...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...